Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
RU-58841
Also known as: RU58841, PSK-3841
RU-58841 is a non-steroidal topical anti-androgen that was developed in the 1990s by Roussel Uclaf for androgenetic alopecia. Despite promising preclinical results, it was never brought to market and clinical development was abandoned. It remains a popular research chemical in the hair loss community, applied topically to block DHT at the follicle.
Risk Level
Medium RiskDifficulty
Advanced| CAS Number | 154992-24-2 |
| Molecular Formula | C17H18F3N3O3 |
| Class | Other |
| Category | Hair Loss Compounds |
Mechanism of Action
RU-58841 is a potent androgen receptor antagonist that competitively binds to the androgen receptor in hair follicle cells, preventing DHT and testosterone from triggering follicular miniaturization. When applied topically, it has high local activity with minimal systemic absorption due to rapid hydrolysis in blood. This provides a theoretical advantage over systemic 5-AR inhibitors by blocking androgens locally without affecting serum hormone levels.
Dosing Research
Common protocol: 25-50 mg dissolved in a vehicle (ethanol/propylene glycol) applied topically to the scalp once daily. Must be mixed fresh or stored properly as the compound degrades. No pharmaceutical-grade product exists; users rely on raw powder from research chemical suppliers. No human clinical data to establish optimal dosing.
Side Effects & Risks
Limited safety data. Potential for scalp irritation and contact dermatitis. Systemic absorption is thought to be minimal but has not been rigorously studied in humans. No long-term safety data. Quality and purity of research chemical sources varies widely. Risk of unknown degradation products. No regulatory oversight of products.
Research Studies
Related compounds
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.